-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $7

Benzinga·03/31/2025 13:54:02
Listen to the news
Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $10 to $7.